Noah A. Levit

864 total citations
28 papers, 604 citations indexed

About

Noah A. Levit is a scholar working on Dermatology, Immunology and Allergy and Physiology. According to data from OpenAlex, Noah A. Levit has authored 28 papers receiving a total of 604 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Dermatology, 17 papers in Immunology and Allergy and 11 papers in Physiology. Recurrent topics in Noah A. Levit's work include Dermatology and Skin Diseases (24 papers), Allergic Rhinitis and Sensitization (15 papers) and Asthma and respiratory diseases (11 papers). Noah A. Levit is often cited by papers focused on Dermatology and Skin Diseases (24 papers), Allergic Rhinitis and Sensitization (15 papers) and Asthma and respiratory diseases (11 papers). Noah A. Levit collaborates with scholars based in United States, Canada and Germany. Noah A. Levit's co-authors include Amanda G. Whitmore, Tianxi Cai, Hansel J. Otero, Dimitrios Mitsouras, Michael L. Steigner, Hale Ersoy, Frank J. Rybicki, Leelakrishna Nallamshetty, Frank J. Rybicki and Marcelo F. Di Carli and has published in prestigious journals such as Journal of Allergy and Clinical Immunology, Journal of Investigative Dermatology and Journal of the American Academy of Dermatology.

In The Last Decade

Noah A. Levit

27 papers receiving 597 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Noah A. Levit United States	10	271	256	189	156	93	28	604
Yasumi Igarashi Japan	14	214 0.8×	8 0.0×	65 0.3×	22 0.1×	404 4.3×	36	591
Andreas Naegel Germany	14	27 0.1×	19 0.1×	18 0.1×	15 0.1×	349 3.8×	30	521
R. Marx Germany	11	41 0.2×	9 0.0×	26 0.1×	35 0.2×	139 1.5×	45	393
Wiesław Królikowski Poland	7	16 0.1×	17 0.1×	7 0.0×	54 0.3×	48 0.5×	15	240
Adam Rdzanek Poland	10	77 0.3×	3 0.0×	25 0.1×	15 0.1×	165 1.8×	44	347
Turan Ege Türkiye	10	20 0.1×	9 0.0×	8 0.0×	48 0.3×	135 1.5×	39	297
Kazuaki Fukahara Japan	13	29 0.1×	23 0.1×	4 0.0×	44 0.3×	215 2.3×	67	456
Marek Kowalski Germany	11	29 0.1×	2 0.0×	71 0.4×	18 0.1×	259 2.8×	30	812
Laurent Lalourcey France	7	8 0.0×	63 0.2×	61 0.3×	2 0.0×	312 3.4×	12	441
Sunil K. Das United States	13	69 0.3×	2 0.0×	11 0.1×	36 0.2×	128 1.4×	35	621

Countries citing papers authored by Noah A. Levit

Since Specialization

Citations

This map shows the geographic impact of Noah A. Levit's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Noah A. Levit with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Noah A. Levit more than expected).

Fields of papers citing papers by Noah A. Levit

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Noah A. Levit. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Noah A. Levit. The network helps show where Noah A. Levit may publish in the future.

Co-authorship network of co-authors of Noah A. Levit

This figure shows the co-authorship network connecting the top 25 collaborators of Noah A. Levit. A scholar is included among the top collaborators of Noah A. Levit based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Noah A. Levit. Noah A. Levit is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Bissonnette, Robert, Elena Goleva, Evgeny Berdyshev, et al.. (2025). Dupilumab treatment restores lesional and nonlesional skin barrier function in adults and adolescents with atopic dermatitis irrespective of the filaggrin genotype: Results from an open-label, healthy-control–matched, phase 4 clinical study (BALISTAD). Journal of the American Academy of Dermatology. 92(5). 1132–1136. 3 indexed citations

Guttman‐Yassky, Emma, Michael J. Cork, Jared Jagdeo, et al.. (2025). Dupilumab Treatment Improves Lichenification in Atopic Dermatitis in Different Age and Racial Groups. Journal of Drugs in Dermatology. 24(2). 167–173. 2 indexed citations

Alexis, Andrew, Zhixiao Wang, Noah A. Levit, et al.. (2025). Development of novel patient-reported outcome instruments to assess atopic dermatitis-associated dyspigmentation and xerosis in patients with skin of colour. British Journal of Dermatology. 192(5). 863–873. 1 indexed citations

Kwatra, Shawn G., Sonja Ständer, Gil Yosipovitch, et al.. (2024). Pathophysiology of Prurigo Nodularis: Neuroimmune Dysregulation and the Role of Type 2 Inflammation. Journal of Investigative Dermatology. 145(2). 249–256. 7 indexed citations

Kwatra, Shawn G., Gil Yosipovitch, Sonja Ständer, et al.. (2023). 42275 Dupilumab Improves Itch, Skin Pain, and Sleep in Adult Patients With Prurigo Nodularis (LIBERTY PN-PRIME and PRIME2). Journal of the American Academy of Dermatology. 89(3). AB40–AB40. 1 indexed citations

Briggs, Emily, Mohamed Kamal, Matthew P. Kosloski, et al.. (2023). Integrated Exposure–Response of Dupilumab in Children, Adolescents, and Adults With Atopic Dermatitis Using Categorical and Continuous Efficacy Assessments: A Population Analysis. Pharmaceutical Research. 40(11). 2653–2666. 1 indexed citations

Silverberg, Jonathan I., Charles Lynde, Katrina Abuabara, et al.. (2023). Efficacy and Safety of Dupilumab Maintained in Adults ≥ 60 Years of Age with Moderate-to-Severe Atopic Dermatitis: Analysis of Pooled Data from Four Randomized Clinical Trials. American Journal of Clinical Dermatology. 24(3). 469–483. 12 indexed citations

Siegfried, Elaine C., Eric L. Simpson, Michael J. Cork, et al.. (2023). Dupilumab Treatment Leads to Rapid and Consistent Improvement of Atopic Dermatitis in All Anatomical Regions in Patients Aged 6 Months to 5 Years. Dermatology and Therapy. 13(9). 1987–2000. 3 indexed citations

Cork, Michael J., Diamant Thaçi, Lawrence F. Eichenfield, et al.. (2023). Dupilumab Safety and Efficacy in a Phase III Open-Label Extension Trial in Children 6–11 Years of Age with Severe Atopic Dermatitis. Dermatology and Therapy. 13(11). 2697–2719. 16 indexed citations

10.

Leung, Donald Y.M., Robert Bissonnette, Simion Kreimer, et al.. (2023). Dupilumab Inhibits Vascular Leakage of Blood Proteins Into Atopic Dermatitis Skin. The Journal of Allergy and Clinical Immunology In Practice. 11(5). 1421–1428. 12 indexed citations

11.

Wollenberg, Andreas, Danielle Marcoux, Jonathan I. Silverberg, et al.. (2022). Dupilumab Provides Rapid and Sustained Improvement in SCORing Atopic Dermatitis Outcomes in Paediatric Patients with Atopic Dermatitis. Acta Dermato Venereologica. 102. adv00726–adv00726. 8 indexed citations

12.

Silverberg, Jonathan I., Mark Boguniewicz, Jon M. Hanifin, et al.. (2022). Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis is Efficacious Regardless of Age of Disease Onset: a Post Hoc Analysis of Two Phase 3 Clinical Trials. Dermatology and Therapy. 12(12). 2731–2746. 7 indexed citations

13.

Berdyshev, Evgeny, Elena Goleva, Robert Bissonnette, et al.. (2022). Dupilumab significantly improves skin barrier function in patients with moderate‐to‐severe atopic dermatitis. Allergy. 77(11). 3388–3397. 77 indexed citations

14.

Haddad, El‐Bdaoui, Sonya Cyr, Kazuhiko Arima, et al.. (2022). Current and Emerging Strategies to Inhibit Type 2 Inflammation in Atopic Dermatitis. Dermatology and Therapy. 12(7). 1501–1533. 47 indexed citations

15.

Paller, Amy S., Elaine C. Siegfried, Michael J. Cork, et al.. (2022). Laboratory Safety from a Randomized 16-Week Phase III Study of Dupilumab in Children Aged 6 Months to 5 Years with Moderate-to-Severe Atopic Dermatitis. Pediatric Drugs. 25(1). 67–77. 4 indexed citations

16.

Beck, Lisa A., Mette Deleuran, Robert Bissonnette, et al.. (2022). Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis. American Journal of Clinical Dermatology. 23(3). 393–408. 66 indexed citations

17.

Wollenberg, Andreas, Lisa A. Beck, Mette Deleuran, et al.. (2022). Safety of Long-Term Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis up to 172 Weeks: Results from an Open-Label Extension (OLE) Trial. Journal of Allergy and Clinical Immunology. 149(2). AB10–AB10. 2 indexed citations

18.

Steigner, Michael L., Dimitrios Mitsouras, Amanda G. Whitmore, et al.. (2009). Iodinated Contrast Opacification Gradients in Normal Coronary Arteries Imaged With Prospectively ECG-Gated Single Heart Beat 320-Detector Row Computed Tomography. Circulation Cardiovascular Imaging. 3(2). 179–186. 119 indexed citations

19.

Steigner, Michael L., Hansel J. Otero, Tianxi Cai, et al.. (2008). Narrowing the phase window width in prospectively ECG-gated single heart beat 320-detector row coronary CT angiography. International journal of cardiac imaging. 25(1). 85–90. 135 indexed citations

20.

Lu, Michael T., Tianxi Cai, Hale Ersoy, et al.. (2008). Comparison of ECG-gated versus non-gated CT ventricular measurements in thirty patients with acute pulmonary embolism. International journal of cardiac imaging. 25(1). 101–107. 49 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact